rhuMAb-E25 anti-IgE monoclonal antibody: Phase II/III

GNE's anti-IgE MAb reduced allergic symptoms in a Phase II/III trial in 536 patients during the pollen season (see BioCentury, Part I). Patients received either 300, 150 or 50 mg of E25 or placebo over 12 weeks beginning 2 weeks prior to the start of pollen season. Use of antihistamines and decongestants was less in the treated group compared to placebo. No antibodies developed to the agent. Findings were presented at the American College of Allergy, Asthma, and Immunology meeting in Philadelphia. ...